Rhythm Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Rhythm Pharmaceuticals Inc.
- Former names
- Rhythm Metabolic, INC.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RYTM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001649904
- EIN
- 46-2159271
Board of directors
-
Camille L. Bedrosian · DirectorSince 2023
-
Christophe Jean · DirectorSince 2023
-
David P. Meeker · Director · President and CEOSince 2023
-
David W. J. Mcgirr · DirectorSince 2023
- Since 2023
-
Jennifer L. Good · DirectorSince 2023
-
Kimberly J. Popovits · DirectorSince 2026
-
Lynn A. Tetrault · DirectorSince 2023
-
Stuart A. Arbuckle · DirectorSince 2023
Chief executives
David P. Meeker
· President and CEO
Dates unknown
Director election results
Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.9%
-
96.9%
Board connections
7 of this board's directors also sit on 14 other boards.
- via David P. Meeker, Edward T. Mathers and Jennifer L. Good
- via David P. Meeker and Kimberly J. Popovits
- via Kimberly J. Popovits
- via Stuart A. Arbuckle
- via Lynn A. Tetrault
- via David W. J. Mcgirr
- via Kimberly J. Popovits
- via Edward T. Mathers
- via Lynn A. Tetrault
- via Edward T. Mathers
- via David P. Meeker
- via Stuart A. Arbuckle
- via Edward T. Mathers
- via David W. J. Mcgirr
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $41,708,131
- 55 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Option exercise | +50,000 | $6.05 | $302,500 |
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Open-market sale | −6,439 | $101.75 | $655,145 |
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Open-market sale | −30,746 | $102.35 | $3,146,761 |
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Open-market sale | −8,698 | $103.43 | $899,634 |
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Open-market sale | −1,817 | $104.55 | $189,965 |
| Sep 14, 2026 | David P. Meeker Director, Officer (President and CEO) | Open-market sale | −2,300 | $105.19 | $241,937 |
| Aug 31, 2026 | Hunter C. Smith Officer (Chief Financial Officer) | Option exercise | +57,187 | $25.79 | $1,474,853 |
| Aug 31, 2026 | Hunter C. Smith Officer (Chief Financial Officer) | Open-market sale | −23,072 | $104.59 | $2,413,034 |
| Aug 31, 2026 | Hunter C. Smith Officer (Chief Financial Officer) | Open-market sale | −11,514 | $105.37 | $1,213,232 |
| Aug 31, 2026 | Hunter C. Smith Officer (Chief Financial Officer) | Open-market sale | −28,188 | $106.20 | $2,993,647 |
| Aug 13, 2026 | Lee Jennifer Kayden Officer (EVP, Head of North America) | Option exercise | +35,000 | $24.29 | $850,150 |
| Aug 13, 2026 | Garfield Alastair Officer (Chief Scientific Officer) | Open-market sale | −2,007 | $116.11 | $233,031 |
| Aug 13, 2026 | Shulman Joseph Officer (Chief Technical Officer) | Option exercise | +2,024 | $6.80 | $13,763 |
| Aug 13, 2026 | Lee Jennifer Kayden Officer (EVP, Head of North America) | Option exercise | +21,601 | $6.80 | $146,887 |
| Aug 13, 2026 | Garfield Alastair Officer (Chief Scientific Officer) | Open-market sale | −1,556 | $117.08 | $182,170 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.